Blood Test Can Predict Clinical Response to Immunotherapy in Metastatic Non-Small Cell Lung Cancer
Perelman School of Medicine at the University of PennsylvaniaNon-small cell lung cancer (NSCLC) patients with higher measures of tumor mutations that show up in a blood test generally have a better clinical response to PD-1-based immunotherapy treatments than patients with a lower measure of mutations.